大理药业(603963) - 2021 Q1 - 季度财报

Financial Performance - Operating revenue for the first quarter reached CNY 48,999,329.56, representing a 9.99% increase year-on-year[8] - Net profit attributable to shareholders was CNY 189,613.98, a significant recovery from a loss of CNY 1,129,581.90 in the same period last year[8] - Basic and diluted earnings per share were both CNY 0.0009, compared to a loss of CNY 0.0051 per share in the previous year[9] - Total operating revenue for Q1 2021 was CNY 48,999,329.56, an increase of 10.3% compared to CNY 44,549,193.86 in Q1 2020[27] - Net profit for Q1 2021 was CNY 189,613.98, a significant recovery from a net loss of CNY 1,129,581.90 in Q1 2020[28] - The total comprehensive income for Q1 2021 was CNY 341,177.15, compared to a total comprehensive loss of CNY -473,487.06 in Q1 2020[33] Cash Flow - The net cash flow from operating activities improved to -CNY 1,901,446.89, a significant reduction from -CNY 9,793,331.64 in the same period last year[8] - The company's cash flow from operating activities for Q1 2021 was CNY -1,901,446.89, an improvement compared to CNY -9,793,331.64 in Q1 2020[16] - The company reported a net cash flow from financing activities of 9,705,722.22 RMB, slightly down from 10,000,000.00 RMB in Q1 2020[40] - The company generated CNY 52,425,098.38 in cash from sales of goods and services, an increase from CNY 49,142,619.06 in the same period last year[35] - Cash outflows for operating activities totaled 51,412,147.22 RMB in Q1 2021, down from 58,065,796.64 RMB in Q1 2020, marking a 11.4% decrease[39] Assets and Liabilities - Total assets increased by 1.52% to CNY 587,528,528.32 compared to the end of the previous year[8] - The total liabilities increased to CNY 116,465,859.09 in Q1 2021 from CNY 107,856,658.91 in Q1 2020, representing a rise of approximately 9.93%[20] - Total assets as of March 31, 2021, amounted to CNY 589,347,693.12, compared to CNY 579,813,325.14 at the end of 2020, indicating a growth of 1.9%[25] - Total liabilities as of March 31, 2021, were CNY 112,811,186.19, an increase from CNY 103,617,995.36 at the end of 2020, representing an increase of 8.3%[25] - Current assets totaled CNY 392,083,809.53 as of March 31, 2021, compared to CNY 388,985,590.62 at the end of 2020, showing a growth of 0.3%[24] Shareholder Information - The total number of shareholders reached 12,002, indicating a stable shareholder base[12] - The largest shareholder, Yang Junxiang, holds 25.50% of the shares, while the second-largest shareholder, Lixing Industrial Co., Ltd., holds 18.75%[12] Expenses - Research and development expenses decreased significantly by 77.45% to CNY 286,045.07 in Q1 2021 from CNY 1,268,222.49 in Q1 2020[19] - The company's management expenses rose by 68.37% to CNY 8,944,249.36 in Q1 2021, primarily due to increased losses from work stoppages compared to the same period last year[19] - Total operating costs for Q1 2021 were CNY 50,787,850.90, up from CNY 46,427,462.93 in Q1 2020, reflecting a rise of 9.7%[27] Government Support - Government subsidies recognized in the current period amounted to CNY 51,020.90, contributing positively to the financial results[11] - The company reported a total of CNY 1,686,502.27 in non-recurring gains and losses for the period[11]